The new frontier in bone and joint disorders.

We develop a compound that is unique, safe and target a specific enzyme for treatment of rare bone diseases. 

Explore Our Science

A digital illustration of a knee joint, highlighting an area of inflammation or injury with a glowing effect.
A digital illustration of a knee joint, highlighting an area of inflammation or injury with a glowing effect.
A digital illustration of a knee joint, highlighting an area of inflammation or injury with a glowing effect.

Innovation is our Foundation.
Science is our Method.

We are developing first-in-class small molecule inhibitors for the treatment of rare bone diseases.

Our highly selective, non-retinoid compounds are designed to modulate local retinoic acid signaling with an excellent safety profile and therapeutic index, supported by strong efficacy in relevant preclinical models.

Diseases We Target

Selective Modulation of the Retinoic Acid Pathway for Safer Therapy

X-ray image of a person with Hereditary Multiple Osteochondromas, showing both legs with bone lesions near the knees.

MO

Lorem Ipsum

A rare genetic disorder of new bone formation in children. It causes reduced skeletal growth, bone deformities, short stature, scoliosis, premature osteoarthritis, and can lead to malignant sarcomas.

  • Currently no cure.

  • Patients often undergo +40 surgeries by age 18.

  • Conventional treatment includes invasive interventions.

X-ray image of a person with Hereditary Multiple Osteochondromas, showing both legs with bone lesions near the knees.

MO

Hereditary Multiple Osteochondromas

A rare genetic disorder of new bone formation in children. It causes reduced skeletal growth, bone deformities, short stature, scoliosis, premature osteoarthritis, and can lead to malignant sarcomas.

  • Currently no cure.

  • Patients often undergo +40 surgeries by age 18.

  • Conventional treatment includes invasive interventions.

X-ray image of a person's left shoulder and upper arm, with Fibrodysplasia Ossificans Progressiva showing the bones and joints.

FOP

Lorem Ipsum

An ultra-rare genetic disease that causes ossification of muscles and connective tissue. This leads to painful and progressive impairment of movement; patients typically require a wheelchair by age 30 and have a life expectancy of about 56 years.

  • Currently no cure.

  • Conventional treatment is only supportive.

  • There is one drug approved but is limited for pediatric use.

X-ray image of a person's left shoulder and upper arm, with Fibrodysplasia Ossificans Progressiva showing the bones and joints.

FOP

Fibrodysplasia Ossificans Progressiva

An ultra-rare genetic disease that causes ossification of muscles and connective tissue. This leads to painful and progressive impairment of movement; patients typically require a wheelchair by age 30 and have a life expectancy of about 56 years.

  • Currently no cure.

  • Conventional treatment is only supportive.

  • There is one drug approved but is limited for pediatric use.

X-ray image of a person with Hereditary Multiple Osteochondromas, showing both legs with bone lesions near the knees.

MO

Hereditary Multiple Osteochondromas

A rare genetic disorder of new bone formation in children. It causes reduced skeletal growth, bone deformities, short stature, scoliosis, premature osteoarthritis, and can lead to malignant sarcomas.

  • Currently no cure.

  • Patients often undergo +40 surgeries by age 18.

  • Conventional treatment includes invasive interventions.

X-ray image of a person's left shoulder and upper arm, with Fibrodysplasia Ossificans Progressiva showing the bones and joints.

FOP

Fibrodysplasia Ossificans Progressiva

An ultra-rare genetic disease that causes ossification of muscles and connective tissue. This leads to painful and progressive impairment of movement; patients typically require a wheelchair by age 30 and have a life expectancy of about 56 years.

  • Currently no cure.

  • Conventional treatment is only supportive.

  • There is one drug approved but is limited for pediatric use.

Unique, Selective and Targeted

Unique, Selective and Targeted

Unique, Selective and Targeted

Non-Retinoid Innovation

A novel approach that modulates the retinoic acid pathway without using retinoids, offering improved safety and selectivity.

Non-Retinoid Innovation

A novel approach that modulates the retinoic acid pathway without using retinoids, offering improved safety and selectivity.

Our Pipeline

Progress Toward Treatment

Phases

Target Discovery

Target Discovery

Target Discovery

Preclinical

Preclinical

Preclinical

IND-Enabling

IND-Enabling

IND-Enabling

Clinical

Clinical

Clinical

Regulatory

Regulatory

Regulatory

Hereditary Multiple Osteochondromas (MO)

Hereditary Multiple Osteochondromas (MO)

Hereditary Multiple Osteochondromas (MO)

Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva (FOP)

Meet the Team

Strategic Partnership - To be announced soon

Strategic
Partnership

Get in Touch

If you're interested in scientific collaboration, partnership opportunities, or want to learn more about our mission, please reach out.